Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 18

recruiting
3 987
countries
28
conditions
2 109

906 trials match your criteria

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Study of Azacitidine, Venetoclax, and Tagraxofusp for Patients with Higher-Risk Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp

Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib

Study on Losartan and Hydrochlorothiazide for Osteogenesis Imperfecta in Patients Aged 16 and Above

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrochlorothiazide

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride

Myelofibrosis

Recruiting

Study on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fedratinib
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.